Hydroxyurea exhibits anticancer chemotherapeutic and antiviral activities; it inhibits ribonucleotide reductase, limiting deoxyribonucleotide production and inhibiting DNA synthesis. This compound also treats sickle cell anemia, as it increases NO levels in blood through binding of hemoglobin and stimulates production of fetal hemoglobin which is not affected by the sickle-cell gene mutation. It also treats myeloproliferative disorders and chronic myelogenous leukemia (CML)
| Cas No. | 127-07-1 |
|---|---|
| Purity | ≥98% |
| Formula | CH4N2O2 |
| Formula Wt. | 76.06 |
| IUPAC Name | hydroxyurea |
| Synonym | Hydroxycarbamide; Droxia; Hydrea; Litalir |
| Melting Point | 133-136°C |
| Solubility | Soluble in water or hot alcohol. |
| Appearance | White Crystal Powder |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | H9715 Info Sheet PDF |
|---|
Amaru Calzada A, Pedrini O, Finazzi G, et al. Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients. Exp Hematol. 2013 Mar;41(3):253-60.e2. PMID: 23111067.
Vankayala SL, Hargis JC, Woodcock HL. Unlocking the binding and reaction mechanism of hydroxyurea substrates as biological nitric oxide donors. J Chem Inf Model. 2012 May 25;52(5):1288-97. PMID: 22519847.
